Amplified Sciences

What Amplified Sciences does

Amplified Sciences is a clinical-stage diagnostics company founded in 2016 as a spinout from Purdue University that develops ultra-sensitive optical assays for early cancer detection. Its lead product, PanCystPro™, is a laboratory-developed test (LDT) that uses cyst-fluid biomarker analysis to risk-stratify pancreatic cystic lesions and identify those likely to progress to pancreatic cancer. The underlying technology, BioMatra™, is a proprietary ultra-sensitive optical reporter platform licensed in part from UCSF, combined with a predictive analytics layer that translates optical measurements into a binary risk score. The company is headquartered in West Lafayette, Indiana, and operates a CLIA-certified, CAP-accredited laboratory in Irvine, California that performs the LDT.

The company serves gastroenterologists, pancreaticobiliary surgeons, and the patients they evaluate for pancreatic cystic lesions, addressing a market that third-party projections put at $6.95B by 2030 with a 9% CAGR. Its primary go-to-market is the PanCystPro™ Early Access Program, which offers the LDT to specialist physicians while the company collects clinical utility evidence through the PanAMP study (launched May 2026) to support broader payer coverage and guideline inclusion. Revenue mechanics are expected to be per-test LDT pricing, but no commercial pricing, test volume, or payer contract data has been disclosed.

Amplified Sciences has raised approximately $7.6M cumulatively across multiple seed tranches, a Series Seed Preferred, and non-dilutive NIH/NSF grants, and operates with 1–10 employees. Recent commercial hires from Roche, Exact Sciences, Lucid Diagnostics, and Thermo Fisher suggest a transition from research-stage to commercial-stage execution, though the company remains pre-revenue as of the latest disclosed period.

Name

Amplified Sciences

Legal name

Amplified Sciences, Inc.

Website

https://amplifiedsciences.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Amplified Sciences is a Purdue spinout that operates a CLIA-CAP lab offering PanCystPro™, a laboratory-developed test using its proprietary BioMatra™ optical platform to risk-stratify pancreatic cystic lesions for gastroenterologists and pancreaticobiliary surgeons.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

Keywords

• Clinical diagnostic testing
• Protease activity assays
• Pancreatic cancer diagnostics
• Laboratory developed tests
• Optical reporter platform

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: Revenue generated from CLIA laboratory testing services. PanCystPro test is available as a Laboratory Developed Test (LDT) performed in the company's CLIA-CAP accredited laboratory in Irvine, California. Healthcare providers order tests through the company's healthcare professional portal.
2. Diagnostic Assays and Testing Kits: Future potential revenue from commercialization of diagnostic assay panels. The company has developed research assays in infectious disease, kidney disease, and other cancers beyond pancreatic cancer.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Amplified Sciences offers laboratory-developed diagnostic tests for early detection and risk stratification of debilitating diseases, with its lead product PanCystPro™ providing risk stratification of pancreatic cystic lesions (PCL) using a proprietary multi-analyte panel that measures protease activity in minute volumes (as low as 25 microliters) of pancreatic cyst fluid. Tests are ordered by licensed healthcare providers through a healthcare professional portal and performed as Laboratory Developed Tests in the company's CLIA-CAP accredited laboratory in Irvine, California.

Product overview

Amplified Sciences is a clinical-stage diagnostics company offering laboratory-developed tests powered by its proprietary BioMatra™ platform technology. The company's lead product is PanCystPro™, a multianalyte diagnostic assay for risk stratification of pancreatic cystic lesions that leverages novel protease activity measurement and proprietary algorithms. The BioMatra platform integrates spectroscopy, chemometric tools, chemistry reagents, and machine learning to enable ultrasensitive detection of multiple biomarkers in small sample volumes. The company is also developing research assays for infectious disease, kidney disease, and other cancers through its pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• PanCystPro™ A laboratory-developed diagnostic test that uses a proprietary multi-analyte platform to detect biomarker levels and activity in minute volumes of pancreatic cyst fluid (as low as 25 microliters) for patients diagnosed with pancreatic cystic lesions (PCL). Features a novel protease activity assay and robust algorithm for risk stratification, identifying benign versus potentially malignant cysts, with high negative predictive value.

Quantifiable outcome

• Reduced pancreatic cyst fluid volume required (as low as 25 microliters)
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• AGA (American Gastroenterological Association)coreStrategic or Co-development Partner · 1 June 2026Selected for AGA incubator cohort in 2025 to promote innovation in GI care. GI Opportunity Fund backed the company's Seed+ round in 2026. Company presents at AGA Presidential Plenary and participates in AGA Tech Summit.
• Cedars-Sinai Medical CentercoreStrategic or Co-development Partner · 1 May 2026Principal investigator site for PanAMP multicenter clinical utility study evaluating PanCystPro diagnostic assay for healthcare provider management decisions.
• Beth Israel Deaconess Medical CentercoreStrategic or Co-development Partner · 1 May 2026Principal investigator site for PanAMP multicenter clinical utility study for pancreatic cystic lesion diagnostic assay.
• Indiana University School of MedicinecoreStrategic or Co-development Partner · 1 May 2026Principal investigator site for PanAMP multicenter clinical utility study. Long-standing partnership with Purdue University ecosystem.
• Plug and PlayminorGTM or Marketing Partner · 1 October 2025Selected for inaugural Plug and Play Lifetech accelerator program in Indianapolis, focusing on therapeutics, diagnostics, and medical devices innovation.
• National Center for Disaster Medicine and Public HealthminorStrategic or Co-development Partner · 1 August 2025Partnership to strengthen the nation's emergency response capabilities through collaboration on diagnostic technology development.
• UCSF (University of California, San Francisco)coreTechnology or Integration · 1 June 2025Licensed exclusive patent rights from UCSF for cutting-edge pancreatic cancer detection technology. Secures complementary IP portfolio for the company's diagnostic tests.
• BioTools InnovatorminorGTM or Marketing Partner · 1 June 2025Selected for BioTools Innovator 2025 cohort (1 of 31 from 400+ applicants). Company featured in road show events and voted best video contest winner.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Exact Sciences: Established molecular diagnostics company known for Cologuard (colorectal cancer screening) and Oncotype DX. Amplified Sciences' Director of Commercial previously worked at Exact Sciences, and both companies target early cancer detection and risk stratification using proprietary molecular assays.
• Veracyte: Genomic diagnostics company offering molecular tests for cancer risk stratification including uveal melanoma, prostate, and thyroid cancers. Operates CLIA laboratories similar to Amplified Sciences, with comparable commercial focus on hospital and clinician adoption of proprietary genomic assays.
• Natera: Molecular diagnostics company specializing in cell-free DNA testing across oncology, women's health, and organ transplantation. Comparable in applying proprietary molecular biomarker technology to cancer risk assessment and operating CLIA laboratory infrastructure.
• Caris Life Sciences: Molecular profiling company using proprietary multi-omics platforms (MI Profile, ADAPT) for cancer detection and therapy selection. Comparable in applying multi-analyte molecular approaches and operating CLIA-accredited laboratories serving oncologists and clinical decision-makers.
• Foundation Medicine: Molecular diagnostics company providing comprehensive genomic profiling of tumors (FoundationOne CDx). Operates CLIA-certified laboratories and applies next-generation molecular approaches to cancer risk assessment, comparable to Amplified Sciences' molecular diagnostic focus.
• Personal Genome Diagnostics (PGDx): Cancer genomics company developing plasma-based liquid biopsy and tissue-based genomic profiling tests. Comparable in applying proprietary molecular biomarker technology to cancer detection, monitoring, and treatment selection via CLIA-accredited laboratory services.

Direct peers

• Guardant Health: Leading liquid biopsy company offering blood-based molecular diagnostics for cancer detection and monitoring. Both Amplified Sciences and Guardant Health apply proprietary multi-analyte molecular approaches to early cancer detection and risk stratification, though Amplified Sciences focuses on cyst fluid rather than blood.
• Interpace Biosciences: Molecular diagnostics company specializing in pancreatic cyst risk stratification through its PancraGEN and ThyGeNEXT tests. This is the closest direct competitor to Amplified Sciences' PanCystPro, addressing the same pancreatic cystic lesion market with proprietary molecular testing.
• Lucid Diagnostics: Diagnostics company focused on early detection of esophageal cancer through its EsoGuard test. Comparable as a clinical-stage diagnostics company using proprietary molecular biomarkers for pre-cancerous lesion risk stratification in a single organ-specific niche; Amplified Sciences' Director of Commercial previously worked at Lucid Diagnostics.

Others

• Bio-Techne: Life science tools and diagnostics company providing proteomics reagents, antibodies, and analytical instruments. Comparable as an enabler of proteomics-based biomarker discovery, and a potential acquirer or partner for Amplified Sciences' BioMatra SERS-based platform technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AmpSciences
• YouTubeyoutube.com/watch?v=Mg5segiZRjA
• LinkedInlinkedin.com/company/amplifiedsciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds8 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplified Sciences